# Immunogenicity of Intramuscular and Intradermal IPV

> **NCT04063150** · PHASE4 · TERMINATED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 958 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** fIPV (0.1 mL) ID
- **BIOLOGICAL:** fIPV (0.1mL) IM
- **BIOLOGICAL:** fIPV (0.2mL) IM
- **BIOLOGICAL:** IPV

## Key facts

- **NCT ID:** NCT04063150
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-06
- **Primary completion:** 2020-03-25
- **Final completion:** 2020-03-25
- **Target enrollment:** 958 (ACTUAL)
- **Why stopped:** COVID-19 pandemic
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04063150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04063150, "Immunogenicity of Intramuscular and Intradermal IPV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04063150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*